New Antibody-Drug conjugate 3H-10000 enters human trials for Hard-to-Treat cancers
NCT ID NCT07354711
First seen Jan 22, 2026 · Last updated Jun 23, 2026 · Updated 23 times
Summary
This study tests a new drug called 3H-10000, which is an antibody-drug conjugate designed to target and kill cancer cells. It is for people with advanced lung or stomach cancer that cannot be removed by surgery or has spread. The trial will enroll 170 participants to find the safest dose and see if the drug shrinks tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Cancer Hospital
RECRUITINGBeijing, Beijing Municipality, 100142, China
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
3H-10000 (an antibody-drug conjugate targeting FGFR2b)
What this could lead to
If successful, this could lead to a new treatment option for people with advanced lung or stomach cancer that has not responded to other therapies.
What could go wrong
This is an early-phase trial (Phase I/II) with only 170 participants, so the drug may not prove effective or safe enough for wider use. Side effects could be significant.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.